伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果研究

Research on Clinical Effect of Valaciclovir Antiviral Inhibition Therapy for the Treatment of Frequent Genital Herpes

目的探讨伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果。方法选择我院2013年1月至2016年1月收治的频发性生殖器疱疹患者80例,随机分为4组各20例。Ⅰ组给予患者服用阿昔洛韦,剂量为每次400 mg,每天服用两次,疗程为6个月;Ⅱ组给予患者服用伐昔洛韦,剂量为每次500 mg,每天服用一次,疗程为6个月;Ⅲ组给予患者服用伐昔洛韦,剂量为每次500 mg,每天服用两次,疗程为3个月;Ⅳ组给予患者服用伐昔洛韦,剂量为每次500 mg,每天服用两次,先服用三个月,然后按照每天1次,每次500 mg的剂量再服用3个月。观察和比较各组患者治疗前后的复发次数和不良反应。结果与治疗前对比,各组治疗后复发次数明显减少,差异具有统计学意义(P<0.05);与Ⅳ组对比,Ⅰ组、Ⅱ组、Ⅲ组治疗后复发次数明显更多,P<0.05。各组不良反应发生率比较差异无统计学意义(P>0.05)。结论服用伐昔洛韦,剂量为每次500 mg,每天服用两次,先服用3个月,然后按照每天1次,每次500 mg的剂量再服用3个月,在频发性生殖器疱疹治疗中具有显著的疗效,能够有效地减少疾病复发的次数,并且该治疗方案安全性良好,值得临床广泛应用以及推广。

Objective To discuss the clinical effect of valaciclovir antiviral inhibition therapy for the treatment of frequent genital herpes. Methods 80 cases of patients with frequent genital herpes admitted to our hospital from January 2013 to January 2016 were selected and divided into 4 groups, with 20 cases in each group. Group Ⅰ was given acyclovir with dosage of 400 mg per time, twice a day for six months; Group Ⅱ was given valaciclovir with dosage of 500 mg per time, once a day for six months; Group Ⅲ was given valaciclovir with dosage of 500 mg per time, twice a day for three months; Group Ⅳ was given valaciclovir with dosage of 500 mg per time, twice a day for the first three months and once a day for the later three months. The recurrent frequency before and after treatment and the adverse reactions of patients in each group were observed and compared. Results After treatment, the recurrent frequency decresed singificanfly compared with that before treatment （P 〈0.05）. After treatment, the recurrent frequency of group IV was significantly fewer than that of the other 3 groups （P〈0.05）. No statistical difference was found in the incidence of adverse reactions among 4 groups （P〉0.05）. Conclusions Taking valaciclovir with dosage of 500 mg per time, twice a day for the first three months and then once a day for the later three months, has significant curative effect for the treatment of frequent genital herpes. It can effectively reduce the recurrent frequency of disease, and has high safety. It is worthy of clinical application and popularization.